CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

VA Officials: Impaired Pathologist May Have Caused Three Deaths

Published: Tue, 25 Sep 2018 18:33:18 EDT
A pathologist working while impaired in the Arkansas Veterans Health Care System of the Ozarks gave incorrect diagnoses to three veterans who later died, according to the Veterans Administration.
Medscape Medical News

Patient-Prosthesis Mismatch Common in TAVR, Survival Suffers

Published: Tue, 25 Sep 2018 16:42:48 EDT
An STS/ACC TVT Registry analysis gives the largest review of this complication, but experts suggest that more details are needed to compare risks between balloon-expandable and self-expanding valves.
Medscape Medical News

TAVR Safe With Either of Two Valves, Two Types of Anesthesia

Published: Tue, 25 Sep 2018 16:38:41 EDT
High-risk patients receiving either a self-expandable CoreValve Evolut R or a balloon-expandable SAPIEN 3 valve under either local or general anesthesia had similar outcomes in SOLVE-TAVI.
Medscape Medical News
Displaying results 1-3 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Arena 3 for 3 as Crohn’s drug meets proof-of-concept test

Published: Tue, 25 Sep 2018 13:01:29 +0000
Arena Pharma says its cannabinoid receptor-targeting drug olorinab could help treat the pain associated with Crohn’s disease, one of the most debilitating symptoms of the inflammatory bowel disorder.

TG stock sinks after setback to blood cancer trial

Published: Tue, 25 Sep 2018 12:59:02 +0000
TG Therapeutics has abandoned plans to seek accelerated FDA approval of its ublituximab-umbralisib combination in chronic lymphocytic leukemia. The biotech made the decision because its phase 3 overall response rate data “were not sufficiently mature to conduct the analysis.”

Reata’s bardoxolone hits goals in phase 2 kidney disease trial 

Published: Tue, 25 Sep 2018 12:15:43 +0000
Reata Pharmaceuticals’ bardoxolone has improved kidney function in patients with IgA nephropathy and Type 1 diabetic chronic kidney disease. The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate, a measure of kidney damage.
Displaying results 1-3 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top